RDB 2295 KRAS
The EGFR (Epidermal-Growth-Factor-Receptor) is a central target for colorectal cancer monoclonal antibody
therapy with for example Cetuximab and Panitumumab. However, only a part of the cancer patients respond to this therapy. Somatic mutations in the EGFR downstream pathway can block therapy success, because the signaling pathway is then constitutively active, independent from the EGFR.
Most frequent mutations arise in KRAS gene. Therefor a KRAS mutation analysis of tumor biopsy is a first step for a personalized cancer therapy
AID KRAS Kit enables sensitive screening for most frequent KRAS mutations in exon 2, 3 and 4.
- Sensitive detection of the most frequent mutations of KRAS gene
Sensitivity: down to 4% mutation vs. WT
- PCR with subsequent lineprobe assay
- Specimen: DNA from fresh or FFPE biopsy
- Control bands on every strip show correct DNA isolation, amplification and hybridization
- Results within 4 hours
- Suited for automated systems
- Evaluation and documentation with AID Scanning system